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polymorphism and risk of cervical cancer: an
update by meta-analysis
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Background: The Fas rs180082 polymorphism has been reported to be associated with cervical cancer susceptibility,
yet the results of these previous results have been inconsistent or controversial. The objective of this study was to
explore whether the Fas rs180082 polymorphism confers susceptibility to cervical cancer.
Methods: The relevant studies were identified through a search of PubMed, Excerpta Medica Database (Embase),
Elsevier Science Direct and Chinese Biomedical Literature Database (CBM) until July 2012. The association between the
Fas rs180082 polymorphism and cervical cancer risk was assessed by odds ratios (ORs) together with their 95%
confidence intervals (CIs).
Results: A total of 7 case–control studies were eventually identified. We found no association between Fas rs180082
polymorphism and cervical cancer susceptibility in overall population (G versus A: OR = 1.03, 95% CI = 0.99-1.07,
P = 0.197; AG + GG versus AA: OR = 1.04, 95% CI = 0.98-1.09, P = 0.176; GG versus AA + AG: OR = 1.04, 95% CI = 0.84–
1.31, P = 0.701). In subgroup analysis, similar results were found in Asian (G versus A: OR = 1.06, 95% CI = 0.97–1.15,
P = 0.195; AG + GG versus AA: OR = 1.08, 95% CI = 0.98–1.19, P = 0.176; GG versus AA + AG: OR = 0.97, 95% CI = 0.51–
1.84, P = 0.935) and African (G versus A: OR = 1.01, 95% CI = 0.97-1.15, P = 0.195; AG + GG versus AA: OR = 0.99,
95% CI = 0.91–1.07, P = 0.739; GG versus AA + AG: OR = 1.09, 95% CI = 0.94–1.25, P = 0.745).
Conclusion: This meta-analysis has shown that there is a lack of association of the Fas rs180082 polymorphisms with
cervical cancer susceptibility. However, larger scale primary studies with the consideration of gene–gene and gene–
environment interactions are still required to further evaluate the interaction of Fas rs180082 polymorphism with
cervical cancer susceptibility.
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In recent years, cervical cancer has been the second fre-
quent women malignancy worldwide, with an estimated
global incidence of 493,243 new cases and 273,505
deaths per year [1]. Therefore, it has been advanced and
it is particularly necessary to explain the etiology of cer-
vical cancer.
It is widely accepted that specific human papillomavi-
rus (HPV) types are the central etiologic agent of cer-
vical carcinogenesis. Other environmental and host* Correspondence: mown163@163.com
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reproduction in any medium, provided the orfactors also play important roles in the persistence of
HPV infection and further malignant conversion of cer-
vical epithelium [2]. A number of previous studies had
suggested that the possible correlation between genetic
polymorphisms of cancer susceptibility genes and the
higher risk of human malignant tumors [3,4].
One of the most important mechanisms for HPV in-
fection control of human immune system is to induce
apoptosis of HPV-infected cells [5]. Apoptosis is a
physiological process and it depends on signals from the
cell surface death receptor Fas, which cooperates with
Fas ligand (FasL) to trigger programmed cell death [6]
Fas gene, which is mapped on chromosome 10q24.1,
consists of nine exons and eight introns, is known as atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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family [7]. Downregulation of Fas with resultant resist-
ance to death signals has been reported in various
cancers [8-10], including cervical cancer. Since Fas has
an important role in cervical cancer, any mutations in
the Fas gene affecting the production of Fas may be can-
didate risk factors for the development of this disease.
Fas has several polymorphisms such as Fas rs2234767,
Fas rs180082 and FasL rs763110. In recent years, these
polymorphisms have attracted widespread attention. How-
ever, the majority of studies focused on Fas rs180082
polymorphism.
In particular, the important polymorphism of Fas, the
A/G mutation at position −670 loci, has been intensively
taken into account. Furthermore, the relationship be-
tween Fas rs180082 polymorphism and cervical cancer
risk has been observed in previous studies. Although a
lot of studies had shown the possible involvement of Fas
rs180082 polymorphism in the pathogenesis of cervical
cancer, the results were not always consistent. Most
studies showed that there was a lack of association of
Fas rs180082 polymorphism with cervical cancer risk
[11-15]. However, not all the studies achieve this result
[16]. Furthermore, previous meta-analysis did not in-
clude African population, which may be not comprehen-
sive and may cause some bias to the final result [17].
Therefore, to derive a more precise estimation of the as-
sociation between Fas rs180082 polymorphism and cer-
vical cancer risk, we performed a meta-analysis of all
eligible case–control studies in this article.
Methods
Search strategy selection criteria
We searched electronic databases PubMed, Excerpta
Medica Database (Embase), Elsevier Science Direct and
Chinese Biomedical Literature Database (CBM) updated
on July 2012 for all publications on the association be-
tween Fas rs180082 polymorphism and cervical cancer
susceptibility. The search strategy was based on combi-
nations using the Mesh terms as follows: (“Fas”) in com-
bination with (“polymorphism” or “polymorphisms” or
“variant” or “SNP” or “mutation”) in combination with
(“cervical cancer” or “cervical carcinoma” or “uterine
cervical neoplasm”) for all publications on the associ-
ation between Fas rs180082 polymorphism and cervical
cancer susceptibility. No language or country restrictions
were applied. All eligible studies were retrieved, and
their bibliographies were checked for other relevant pub-
lications. Review articles were also inspected to find add-
itional eligible studies. For the use of these clinical
materials for research purposes, prior consents from the
patients and approval from the Ethics Committees of the
First Affiliated Hospital of Guangxi Medical University
were obtained.Inclusion and exclusion criteria
Studies included in our meta analysis had to meet the
following inclusion criteria: (a) a case–control study;
(b) information on the evaluation of Fas rs180082 poly-
morphisms and cervical cancer risk; (c) the papers must
provide sufficient data including distribution of genotype
and allele frequency; (d) when multiple publications
reported on the same or overlapping data, we chose the
most recent or largest population. Studies were excluded
if one of the following existed: (a) studies that contained
overlapping data; (b) Not offering the source of cases and
controls or other essential information; (c) studies in
which family members had been studied because their
analysis are based on linkage considerations; (d) Reviews
and repeated literature were also excluded.
Data extraction
Two investigators (Xu Chen and Wuning Mo) independ-
ently extracted the information with the standard proto-
col and the result was reviewed by a third investigator
(Qiliu Peng).From each study, the information we
extracted the name of first author, year of publication,
country of origin, ethnicity of the population studied,
the number of cases and controls, allele frequency, def-
inition of cases, and genotype distribution in cases. Dif-
ferent ethnic descents were categorized as White, Asian,
or African. For studies including subjects of different
ethnic groups, data were extracted for ethnic group
whenever possible.
Statistical analysis
Data were analyzed mainly using the STATA Software
(version 9.0, Stata Corp). For each study, odds ratio
(OR) and its 95% confidence interval (95% CI) were cal-
culated to assess the association strength. Meta-analysis
was performed for the polymorphisms that had been in-
vestigated in at least two studies. We examined the rela-
tionship between the allele, as well as genotypes and
susceptibility to cervical cancer. The heterogeneity be-
tween the studies was assessed by the χ2-test based
Q-statistic. A significant Q-statistic (P < 0.10) indicated
heterogeneity among the studies, and so the summary OR
estimate of each study was calculated by the random -
effects model (DerSimonian and Laird method) [18].
Otherwise, the fixed-effects model (the Mantel-Haenszel
method) was used [19]. We also measured the effect of
heterogeneity by another measure, I2 = 100% * (Q–df)/Q
[20]. The I statistic measures the degree of inconsistency
in the studies by calculating what percentage of the total
variation across studies is due to heterogeneity rather
than by chance [21]. The overall estimate of risk (OR)
was calculated by a fixed effects model (Mantel–
Haenszel) or a random effects model (DerSimonian–
Laird) according to the presence (P < 0.10 or I2 > 50%)
Chen et al. BMC Medical Genetics 2013, 14:71 Page 3 of 7
http://www.biomedcentral.com/1471-2350/14/71or absence (P > 0.10 and I2 < 50%) of heterogeneity,
respectively.
Publication bias was observed with the funnel plot
[22] using the standard error of log (OR). An asymmet-
ric plot infers a possible publication bias. Funnel plot
asymmetry was further assessed by the method of Egger
linear regression test. The significance of the intercept
was determined by the Student t test suggested by Egger




Based on the search criteria, the literature search identi-
fied 17 related articles relevant to the role of the Fas
rs180082 polymorphism on cervical cancer susceptibil-
ity. Eleven of these articles were excluded: one of these
articles was a review [23], one was an overlapped subject
[24], one was not a case–control study [25], one did not
focus on the locus that we study [26], two focused on
the subjects that were not relevant to cervical cancer
[27,28], two were not associated with the aim of our
study [29,30], and three did not provide enough allele or
genotyping data [31-33]. Manual search of references
cited in the published studies did not reveal any add-
itional articles. As a result, a total of 6 relevant studies
met the inclusion criteria for the meta-analysis [11-16].
A flow diagram of the search process is shown in Figure 1.
Therefore, a total of 7 separate case–control studies,
consisting of 1,856 cervical cancer patients and 2,097Figure 1 The forest plot describing the meta-analysis with a fixed-eff
rs180082 polymorphism with cervical cancer. Each study is depicted w
respective 95% confidence intervals. Values of OR > 1, implied an increasedcontrols were included in our meta-analysis ([11] litera-
ture has two case–control studies). The selected study
characteristics were listed in Table 1. There were 4 case–
control studies of subjects of Asian descent [12-14,16], 2
case–control studies of subjects of African descent [11]
and one case–control study of subject of White descent
[15]. The genotype frequencies for control group in two
studies were not consistent with Hardy-Weinberg equilib-
rium (HWE) [11,13].Quantitative synthesis of data
Summary results of this meta-analysis for the association
between Fas rs180082 polymorphism and cervical can-
cer risk are shown in Table 2. The meta-analysis showed
no association between cervical cancer and the Fas -
670G allele in the overall population (OR=1.03, 95% CI=
0.99-1.07, P=0.197; Figure 2). The overall OR for the GG+
GA genotype of the Fas −670 was 1.04 in the overall
population (95% CI=0.98-1.09, P=0.176). The overall OR
for the GG genotype of the Fas −670 was 1.04 in the over-
all population (95% CI=0.84-1.31, P=0.701). Stratification
by ethnicity revealed still no association of the G allele,
and the GG and the GG + GA genotypes with cervical
cancer in Asian and African (Table 2).Sensitivity analysis
Although 2 studies [11,13] did not follow the HWE, the
summary ORs were not effectively altered including or
without including the studies. Moreover, no other singleect recessive model (G versus A) for the association of Fas
ith size inversely proportional to its variance, accompanied by the
risk for cervical cancer with the G allele.
Table 1 Main characteristics of studies included in the meta-analysis
First author Year Country Ethnicity Genotyping method Source of control Cases/controls HWE-control
Li H 2009 China Asian PCR-PFLP HB 314/615 0.640
Kordi T 2008 India Asian PCR-PFLP HB 200/200 0.000
Sokbom K 2007 South Korea Asian PCR-PFLP HB 154/160 0.264
Ueda M 2006 Japan Asian PCR-PFLP HB 83/95 0.172
Zoodsma M 2005 Netherlands White Taq Man PB 670/607 0.274
Kooshik C 2009 South Africa African Taq Man HB 106/101 0.047
Kooshik C 2009 South Africa African Taq Man HB 341/323 0.985
PCR-RFLP PCR-restriction fragment length polymorphism, HWE Hardy-Weinberg equilibrium, HB hospital based, PB population based.
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cated by sensitivity analysis.
Test of heterogeneity
There was significant heterogeneity for heterozygote
comparison of dominant model comparison (GA+AA vs.
GG: P = 0.007) and recessive model comparison (GG vs.
GA+AA: P= 0.001). Then, we assessed the source of het-
erogeneity for heterozygote comparison (GA+AA vs.
GG) by ethnicity. As a result, ethnicity (χ2 = 14.41; df = 2;
P = 0.001) was found to contribute to substantial
heterogeneity.
Publication bias
Begg funnel plot was created to assess the publication
bias of literatures. As shown in Figure 3, the shapes of
the funnel plots did not reveal any evidence of obvious
asymmetry. Then, the Egger test was used to provide
statistical evidence of funnel plot symmetry. The results
still also suggested the absence of publication bias
(t=1.93; P=0.112 for G vs. A).
Discussion
The alterations of apoptosis-related genes are probably
contributing to malignant tumors, including cervical
cancer [34]. Fas is an important apoptosis-related geneTable 2 Results of meta-analysis for the Fas rs180082 polymo
Comparison Population N Sample size T
Case Control OR
G vs. A Overall 7 3712 4194 1.03
Asian 4 1502 2140 1.06
Afrian 2 870 840 1.01
GG+GA vs. AA Overall 7 1856 2097 1.04
Asian 4 751 1070 1.08
Afrian 2 435 420 0.99
GG vs. GA+AA Overall 7 1856 2097 1.04
Asian 4 751 1070 0.97
Afrian 2 435 420 1.09
OR odds ratio, CI confidence interval, F fixed effects model, R random effects modeand known as a member of tumor necrosis factor (TNF)
receptors superfamily [7]. Downregulation of Fas with
resultant resistance to death signals has been reported in
many cancers [23]. Furthermore, the transcript expres-
sion of Fas is modulated by genetic elements which lo-
cated in the 5′ upstream promoter region of the gene.
SNP at −670 in the enhancer region (A/G) locates at a
binding element of gamma interferon activation signal
(GAS). Homozygous for G allele (GG) could lead to a
complete deletion of the binding sequence of transcrip-
tion element GAS, which is responsible for the signal
emanated through STAT1, and in a significant alteration
in the gene expression [35].
Although previous meta-analysis maybe involves some
parts of the relationship between Fas rs180082 poly-
morphism and cervical cancer risk, its eligible studies
are not quite comprehensive [17]. First, lack of the
population of African, which leads to the decrease of
studies and may cause a deviation to final result; second,
some of the its eligible studies regard squamous cell car-
cinoma (SCC) or squamous intraepithelial lesion (SIL)
as the cervical cancer [29,33]. However, SCC is just one
pathological type of cervical cancer and SIL is just a
stage in the pathological process of cervical cancer,
which may also bring some bias. Therefore, we conduct
an update by meta-analysis to comprehensively evaluaterphism and cervical cancer risk
est of association Mode Test of heterogeneity
95% CI P χ2 P I2
0.99-1.07 0.197 F 7.38 0.288 18.6
0.97-1.15 0.195 F 4.76 0.190 37.0
0.95-1.08 0.776 F 1.88 0.170 46.9
0.98-1.09 0.176 R 17.75 0.007 66.2
0.98-1.19 0.125 R 6.90 0.075 56.5
0.91-1.07 0.739 R 5.65 0.017 82.3
0.84-1.31 0.701 F 21.56 0.001 72.2
0.51-1.84 0.935 R 18.34 0.000 83.6
0.94-1.25 0.245 F 0.82 0.364 0.0
l.
Figure 2 Forest plot of cervical cancer risk associated with Fas rs180082 (G versus A). The squares and horizontal lines correspond to the
study-specific OR and 95% CI. The area of the squares reflects the study-specific weight (inverse of the variance). The diamond represents the
summary OR and 95% CI.
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cervical cancer risk. This update meta-analysis includes
seven latest case–control studies, five of which are pub-
lished in recent 5 years. Despite the number of eligible
studies in this meta-analysis is still infinite, all the stud-
ies included in this meta-analysis, which are based on
stricter search criteria, are more reliable and lead to a
more accurate result.
As for cervical cancer risk, the previous results of the
studies involving Fas rs180082 polymorphism were
contradictory. These inconsistent results were possibly
due to small effect of the polymorphism on cervical can-
cer risk or the relatively low statistical power of the pub-
lished studies. Consequently, the meta-analysis was
needed to provide a quantitative approach for combiningFigure 3 Begg funnel plot for publication bias test (G versus A). Each
[OR], natural logarithm of OR. Horizontal line means effect size.the results of various studies with the same topic and for
estimating and explaining their diversity.
So far, the number of the studies that focus on the re-
lationship between Fas rs180082 polymorphism and
cancer risk is limited. Some studies before had shown
that there was an association between Fas rs180082 and
some cancers, including nasopharyngeal carcinoma [36],
lung cancer [37,38], gastric cancer [39] and leukemia
[40]. Otherwise, some studies draw a different conclu-
sion [41].
The studies included in our meta-analysis may differ
in some aspects. Koushik, et al. conducted the first African
population study with 447 women with invasive cervical
cancer and 424 healthy women controls [11]. Li, et al.
conducted the study with 314 women of cervical cancerpoint represents a separate study for the indicated association. Log
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Kordi, et al. conducted the first study in North India [13].
Zoodsma, et al. and Kang, et al. conducted the same study
in Netherland and South Korea [14,15]. All of them did
not find any significant association between Fas rs180082
polymorphism and cervical cancer susceptibility. However,
Ueda, et al. found that polymorphism of Fas gene pro-
moter −670 may be associated with the risk of cervical
cancer in a Japanese population. It should be pointed out
that the study which focused on Japanese population is
based on small sample size (<200 subjects), so that we
should be cautious to the result of this study. Conse-
quently, our data failed to find a relationship between Fas
rs180082 polymorphism and cervical cancer risk. The
present meta-analysis, which included 1856 cases of cer-
vical cancer and 2097 controls, suggested that there was
no association between Fas rs180082 polymorphism and
cervical cancer susceptibility.
Considering the results may be due to different ethni-
city, we further conducted subgroup analysis according
to ethnicity. When stratifying for ethnicity, significant
association was detected in neither Asian populations
nor African populations, suggesting that the genetic
background or environment they live in may not influ-
ence the Fas rs180082 polymorphism on cervical cancer
susceptibility. However, the conclusion should be cau-
tious. Because the sample size of studies included in our
meta-analysis is relatively small, especially in the African
population. Our results may be underpowered so that
further studies need to be conducted to increase the
statistical power. The genetic distance between different
ethnicities considered together could be substantial. It is
not excluded that true effects are present in one specific
sub-population, but undetected due to lack of statistical
power or diluted/cancelled out by population stratifica-
tion issues when different study populations are grouped
together for analysis.
Some limitations of this meta-analysis we need to pay
attention to. First, our results are based on unadjusted
estimates and a more precise analysis stratified by age,
different lifestyle related habits and different grades of
cervical cancer could be performed if individual data
were available. Second, lack of the original data of the
reviewed studies limited our precise estimation of the re-
lation, which might cause some bias. Third, the lack of
original study limited our further evaluation of potential
interactions because the interactions between gene-
environment interactions may modulate cancer risk.
Despite these limitations or disadvantages, our meta-
analysis still had some advantages. First, a systematic re-
view of the association of Fas rs180082 polymorphism
with cervical cancer risk is statistically more powerful
than any single study. Second, the studies retrieved were
the latest, half of which were published in the recent3 years. Third, the quality of case–control studies in-
cluded in our Meta analysis was satisfactory and met our
inclusion criteria.
Conclusions
In summary, the present meta-analysis provides infor-
mation that there is a lack of association of the Fas
rs180082 polymorphisms with cervical cancer. However,
larger scale primary studies with the consideration of
gene–gene and gene–environment interactions are still re-
quired to further evaluate the interaction of Fas rs180082
polymorphism with cervical cancer susceptibility.
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